J&P Medi announced that it has been selected as the recipient of the Incheon Future Innovation Company Award, hosted by Incheon Technopark. The awards ceremony took place at the "2025 Incheon Partners Day" event hosted by Incheon Technopark.
The Incheon Future Innovation Company Award recognizes small and medium-sized enterprises with high future growth potential through a comprehensive evaluation of technological innovation, market competitiveness, and business model scalability. J&P Medi received high praise for leading the digital transformation of the entire clinical trial lifecycle through its AI-based clinical trial data management and operations platform and for demonstrating its commercial competitiveness.
J&P Medi has been leveraging AI technology to automate and enhance clinical trial data management, thereby simultaneously strengthening its domestic and international regulatory compliance capabilities and operational efficiency. With this award, the company plans to further develop its AI-based clinical data automation and regulatory compliance technologies, and to accelerate its multinational clinical trials and global market expansion.
The company's core solution, Maven Clinical Cloud, is an AI-based clinical trial data management and operations platform. It automatically detects errors and anomalies occurring during data collection and input, providing researchers with real-time correction guidance. Furthermore, it automatically reviews and refines clinical data, converting it to CDISC standards, thereby helping to meet submission requirements for major regulatory agencies in the US, Europe, and Korea.
Jeong Gwon-ho, CEO of JNP Medi, said that the performance of clinical trials depends on data accuracy and regulatory response capabilities, and that he would continuously increase the efficiency and reliability of clinical trials by automating and standardizing clinical data management, document creation, and regulatory response across the board based on AI technology.
- See more related articles
You must be logged in to post a comment.